Concentration of Credit Risk and Current Expected Credit Losses - Narrative (Details) - USD ($) |
9 Months Ended | 12 Months Ended |
---|---|---|
Sep. 30, 2024 |
Dec. 31, 2023 |
|
Concentration of risk | ||
Allowance for doubtful accounts | $ 0 | $ 0 |
Novartis and Lilly | Accounts Receivable | Credit Concentration Risk | ||
Concentration of risk | ||
Percentage of concentration risk | 21.00% | 20.00% |
Customer A, B, C, D, E and F | Accounts Receivable | Credit Concentration Risk | ||
Concentration of risk | ||
Percentage of concentration risk | 53.00% | 48.00% |
X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|